Alpha Sense BI

AUGUST 30, 2023

As time goes on and more firms adopt AI tools, these capabilities will become even more essential to maintain a competitive advantage. Now integrated into nearly every industry, genAI is fast becoming a must-have for any firm that aims to get the competitive edge.

Management 98

Management Biotech Due Diligence Algorithm 98

Alpha Sense BI

MAY 5, 2023

2023 so far has revealed ideal conditions for dealmaking due to valuation resets, lessened competition for deals, and new assets coming to market. M&A Trends by Industry Healthcare The COVID-19 pandemic ushered in a wave of unprecedented innovation, progress, and transformation to the healthcare industry in 2020.

Biotech 97

Biotech Capital Banking Startups 97

Alpha Sense BI

APRIL 29, 2024

Traditional due diligence for start-up investors has historically been riddled with inefficiencies—tying up resources to sort through countless documents and copious amounts of data, and manually crafting market comparisons and performance. There is no doubt that generative AI has emerged as a powerful tool in the investment space.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

APRIL 19, 2024

2020 and 2021 were marked by increased innovation, accelerated growth, and workforce expansion. Inflationary pressures are forecasted to ease and new innovations are capturing the attention of consumers, investors, and executives across various industries. As we navigate 2024, the landscape appears positioned for a triumphant comeback.

Technology 69

Technology Technology Retail Biotech 69

Engage3

MAY 19, 2022

Ken served on the Board of Directors of Revionics between 2007-2011 and as Chief Scientist & VP of Innovations at SAP AG between 2006-2007. Tim Ouimet Founder & Board Observer Tim Ouimet is a Founder and Board Member at Engage3 and is a recognized industry innovator in retail pricing strategies.

Retail 52

Retail Capital Finance Biotech 52

Alpha Sense BI

MARCH 13, 2024

billion acquisition of Carmot Therapeutics, a clinical-stage biotechnology company with three GLP-1 assets in clinical production, including its CT-388 lead GLP-1 asset, in the hopes of gaining a competitive footing among Novo Nordisk and Eli Lilly’s products currently on the market (Ozempic, Wegovy, and Mounjaro, respectively).

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59